MicroRNA MIR21 and T Cells in Colorectal Cancer

Kosuke Mima, Reiko Nishihara, Jonathan A. Nowak, Sun A. Kim, Mingyang Song, Kentaro Inamura, Yasutaka Sukawa, Atsuhiro Masuda, Juhong Yang, Ruoxu Dou, Katsuhiko Nosho, Hideo Baba, Edward L. Giovannucci, Michaela Bowden, Massimo Loda, Marios Giannakis, Adam J. Bass, Glenn Dranoff, Gordon J. Freeman, Andrew T. Chan, Charles S. Fuchs, Zhi Rong Qian, and Shuji Ogino

Abstract

The complex interactions between colorectal neoplasia and immune cells in the tumor microenvironment remain to be elucidated. Experimental evidence suggests that microRNA MIR21 (miR-21) suppresses antitumor T-cell–mediated immunity. Thus, we hypothesized that tumor MIR21 expression might be inversely associated with T-cell density in colorectal carcinoma tissue. Using 538 rectal and colon cancer cases from the Nurses’ Health Study and the Health Professionals Follow-up Study, we measured tumor MIR21 expression by a quantitative reverse-transcription PCR assay. Densities of CD3+ and CD8+ cells were determined by tissue microarray immunohistochemistry and computer-assisted image analysis. Ordinal logistic regression analysis was conducted to assess the association of MIR21 expression (ordinal quartiles as a predictor variable) with T-cell density (ordinal quartiles as an outcome variable), adjusting for tumor molecular features, including microsatellite instability; CpG island methylator phenotype; KRAS, BRAF, and PIK3CA mutations; and LINE-1 methylation. We adjusted the two-sided α level to 0.012 for multiple hypothesis testing. Tumor MIR21 expression was inversely associated with densities of CD3+ and CD45RO+ cells (P_trend < 0.0005). The multivariate odds ratio of the highest versus lowest quartile of MIR21 for a unit increase in quartile categories of CD3+ or CD45RO+ cells was 0.44 [95% confidence interval (CI), 0.28 to 0.68] or 0.41 (95% CI, 0.26–0.64), respectively. Our data support a possible role of tumor epigenetic deregulation by noncoding RNA in suppressing the antitumor T-cell–mediated adaptive immune response and suggest MIR21 as a potential target for immunotherapy and prevention in colorectal cancer.

Introduction

Accumulating evidence indicates that innate and adaptive immunity influences tumor evolution (1). Attesting to an important role of T-cell–mediated adaptive immunity in inhibiting tumor progression, therapeutic antibodies specific for immune checkpoint molecules, including CTLA4, PDCD1 (programmed cell death 1; PD-1), and CD274 (programmed cell death 1 ligand; PD-L1), can effectively enhance antitumor T-cell activity in various cancers (2, 3). Emerging evidence suggests complex roles of tumor genetic alterations and tumor–host interactions in response to T-cell–based immunotherapies (4, 5). Although these immunotherapies appeared to be less effective for colorectal cancer, intense infiltrates of T cells in colorectal cancer tissue have been associated with better patient survival (6–8), and studies have suggested a potential role of immune checkpoint pathways in suppressing antitumor immune responses in a subset of colorectal cancers (9, 10). A high degree of microsatellite instability (MSI-high) in colorectal cancer is associated with intense infiltrates of T cells, as mismatch repair defects in MSI-high tumors cause numerous frameshift mutations and truncated proteins (neopeptides), which elicit antitumor T-cell–mediated adaptive immunity (11–13). However, MSI status is not the sole determinant of immune response to colorectal cancer, because the numbers of tumor-infiltrating T cells considerably overlap between MSI-high and microsatellite-stable (MSS) colorectal tumors (7, 9, 13). Hence, other factors may influence the antitumor immune response to colorectal cancer.
MicroRNAs (miRNA) are short noncoding RNAs (18–24 nucleotides in length) that play substantial roles in epigenetic gene regulation in diverse biologic and pathologic processes, including immunity and carcinogenesis (14, 15). Among various miRNAs, MIR21 (mir-21) has been shown to play roles in immunity and colorectal carcinogenesis (16–18). In fact, high MIR21 expression in colorectal cancer tissue has been associated with worse clinical outcome, suggesting MIR21 as a prognostic tumor biomarker (19, 20). MIR21 is expressed in colorectal cancer cells (20, 21), and MIR21 increases amounts of IL10 and prostaglandin E2 (PGE2) in the tumor microenvironment (22–24). IL10 and PGE2 can suppress antitumor T-cell–mediated adaptive immunity through inhibition of the antigen-presenting capacities of dendritic cells and recruitment of myeloid-derived suppressor cells into the tumor microenvironment (25, 26). Therefore, we hypothesized that higher MIR21 expression might be associated with fewer T cells in colorectal cancer tissue. A better understanding of the relationship between miRNAs and immune cells in the tumor microenvironment may open opportunities to use miRNAs for immunotherapy and prevention of colorectal cancer.

To test our hypothesis, we analyzed two U.S. nationwide prospective cohort studies [the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS)] and examined tumor MIR21 expression in relation to densities of CD3+, CD8+, CD45RO (PTPRC)+, and FOXP3+ T cells in colorectal cancer tissue.

Materials and Methods

Study population

We used the databases of two U.S. nationwide prospective cohort studies, the NHS (121,701 women who enrolled in 1976) and the HPFS (51,529 men who enrolled in 1986; refs. 27, 28). Every 2 years, participants were sent follow-up questionnaires to gather information on health and lifestyle factors, and to identify newly diagnosed cancers and other diseases. Medical records were reviewed, and the cause of death was assigned by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cancer deaths by study physicians. The National Death Index was used to ascertain deaths of study participants and identify unreported lethal colorectal cance...
and 146; refs. 35, 36), BRAF (codon 600; ref. 30), and PIK3CA (exons 9 and 20; refs. 37, 38).

Immunohistochemistry and quantification of the density of T cells

We constructed a tissue microarray (TMA) and conducted immunohistochemistry for CD3, CD8, CD45RO (one of the PTPRC protein isoforms), and FOXP3 (7). We used an automated scanning microscope and the Ariol image analysis system (Genetix) to measure densities (cells/mm²) of CD3⁺, CD8⁺, CD45RO⁺, and FOXP3⁺ T cells in colorectal cancer tissue as previously described (7).

Statistical analysis

All statistical analyses were conducted using SAS (version 9.3, SAS Institute), and all P values were two-sided. Neither MIR21 expression, T-cell density, nor log-transformed values of MIR21 or T-cell density fit a normal distribution with the use of the Kolmogorov–Smirnov test for normality (P ≤ 0.048). Thus, we tested our primary hypothesis using a linear trend test in an ordinal logistic regression model to assess associations of tumor MIR21 expression (an ordinal quartile predictor variable as a continuous variable) with the density of CD3⁺, CD8⁺, CD45RO⁺, or FOXP3⁺ T cells in colorectal cancer tissue (an ordinal quartile outcome variable). Because we tested four primary hypotheses (for CD3⁺, CD8⁺, CD45RO⁺, and FOXP3⁺ T cells as outcome variables), we adjusted two-sided α level to 0.012 (= 0.05/14) by simple Bonferroni correction for multiple hypothesis testing. All other analyses, including evaluation of individual odds ratio (OR) estimates, represented secondary analyses. In those secondary analyses, in view of multiple comparisons, we interpreted our data cautiously, in addition to the use of the adjusted α level of 0.012.

We performed multivariable ordinal logistic regression analysis to control for potential confounders. The multivariable model initially included age (continuous), sex, year of diagnosis (continuous), family history of colorectal cancer in a first-degree relative (present vs. absent), tumor location (proximal colon vs. distal colon vs. rectum), tumor differentiation (well to moderate vs. poor), MSI (high vs. MSI-low/MSS), CIMP (high vs. low/ negative), KRAS (mutant vs. wild-type), BRAF (mutant vs. wild-type), and PIK3CA (mutant vs. wild-type), and LINE-1 methylation level (continuous). For cases with missing information in any of the covariates, we assigned a separate ("missing") indicator variable. A backward stepwise elimination with a threshold of P = 0.05 was used to select variables in the final models. We assessed the proportional odds assumption in the ordinal logistic regression model, which was generally satisfied (P > 0.05).

All cross-sectional univariable analyses for clinical, pathologic, and molecular associations (with variables listed in Table 2) were secondary exploratory analyses, and we adjusted the two-sided α level to 0.003 (= 0.05/14) by simple Bonferroni correction for multiple hypothesis testing. To assess associations between the ordinal categories (first to fourth quartile) of tumor MIR21 expression and categorical data, the χ² test was performed. To compare mean age and mean LINE-1 methylation levels, an ANOVA assuming equal variances was performed.

Results

MIR21 expression in colorectal cancer

To test the hypothesis of an inverse relationship between MIR21 expression and T-cell infiltration in colorectal cancer tissue, we measured MIR21 expression with RT-PCR assays on 538 colorectal cancer cases within the NHS and the HPFS databases. In 54 pairs of colorectal cancer and adjacent nontumor colonic mucosa, MIR21 expression was generally higher in colorectal cancer than in paired adjacent nontumor colonic mucosa (Wilcoxon signed rank test, P < 0.0001; Fig. 1B).

Table 2 shows the clinical, pathologic, and molecular features of the 538 cases according to tumor MIR21 expression. Higher tumor MIR21 expression was associated with BRAF mutation (P = 0.003; with adjusted α level of 0.003 for multiple hypothesis testing).

Association of tumor MIR21 expression with T-cell density in colorectal cancer tissue

We measured the densities of CD3⁺, CD8⁺, CD45RO⁺, and FOXP3⁺ T cells in colorectal cancer tissue by immunohistochemistry and image analysis. Supplementary Table S1 shows pairwise correlations between the densities of CD3⁺, CD8⁺, CD45RO⁺, and FOXP3⁺ T cells. Except for between CD8⁺ and FOXP3⁺ T cells (P = 0.16), all of the other pairwise correlations were statistically significant (with Spearman rank correlation coefficients ranging from 0.18 to 0.48; all P < 0.0001).

Table 3 shows a distribution of colorectal cancer cases according to tumor MIR21 expression (quartiles) and the density of T cells in colorectal cancer tissue (quartiles). In our primary hypothesis testing, we conducted univariable and multivariable ordinal logistic regression analyses to assess the associations of tumor MIR21 expression (as an ordinal quartile predictor variable) with the density of CD3⁺, CD8⁺, CD45RO⁺, or FOXP3⁺ T cells in colorectal cancer tissue (an ordinal quartile outcome variable; Table 4 and Supplementary Table S2 with all covariates). Tumor MIR21 expression was inversely associated with the densities of CD3⁺ T cells and CD45RO⁺ T cells in unfavorable and
multivariable ordinal logistic regression analyses (all $P_{\text{trend}} < 0.0005$; with adjusted $\alpha$ level of 0.012 for multiple hypothesis testing). Compared with cases in the lowest quartile of tumor MIR21 expression, those in the highest quartile were inversely associated with the densities of CD3$^+$ T cells [multivariable OR, 0.44; 95% confidence interval (CI), 0.28–0.68; for a unit increase in quartile categories] and CD45RO$^+$ T cells (multivariable OR, 0.41; 95% CI, 0.26–0.64; for a unit increase in quartile categories). Tumor MIR21 expression was not significantly associated with the density of CD8$^+$ or FOXP3$^+$ T cells ($P_{\text{trend}} > 0.03$ in univariable analysis with adjusted $\alpha$ level of 0.012). We also used tumor MIR21 expression after adjusting for cellularity in colorectal cancer tissue, and observed similar associations of tumor MIR21 expression with the density of T cells (Supplementary Methods and Supplementary Table S3).

In our exploratory analyses, higher tumor MIR21 expression was significantly associated with higher colorectal cancer–specific mortality ($P_{\text{trend}} = 0.003$), whereas higher CD8$^+$ T-cell density was significantly associated with lower colorectal cancer–specific mortality ($P_{\text{trend}} = 0.012$; Supplementary Methods and Supplementary Table S4).

**Discussion**

We conducted this study to test the hypothesis that tumor MIR21 expression might be inversely associated with the density...
of T cells in colorectal cancer tissue in a human population. We demonstrated that miRNA expression analysis, by RT-PCR assay, on FFPE tissue specimens was feasible and robust, in agreement with results from previous studies (19, 20). Using the database of the 538 colorectal cancer cases in the two U.S. nationwide prospective cohort studies, we found that tumor MIR21 expression was inversely associated with the densities of CD3⁺ and CD45RO⁻ T cells in human colorectal cancer tissue. Our first-line

Table 3. Distribution of colorectal cancer cases according to tumor MIR21 expression and the density of T cells

<table>
<thead>
<tr>
<th>CD3⁺ cell density (quartile)</th>
<th>Total</th>
<th>Q1 (lowest)</th>
<th>Q2 (second)</th>
<th>Q3 (third)</th>
<th>Q4 (highest)</th>
<th>P&lt;sub&gt;trend&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3 (0-115 cells/mm²)</td>
<td>130 (25%)</td>
<td>26 (20%)</td>
<td>29 (22%)</td>
<td>31 (25%)</td>
<td>44 (33%)</td>
<td>0.0004</td>
</tr>
<tr>
<td>CD3 (116-252 cells/mm²)</td>
<td>129 (25%)</td>
<td>26 (20%)</td>
<td>30 (23%)</td>
<td>35 (28%)</td>
<td>38 (29%)</td>
<td>0.05</td>
</tr>
<tr>
<td>CD3 (253-533 cells/mm²)</td>
<td>130 (25%)</td>
<td>42 (32%)</td>
<td>33 (25%)</td>
<td>30 (24%)</td>
<td>25 (19%)</td>
<td>0.10</td>
</tr>
<tr>
<td>CD3 (&gt;534 cells/mm²)</td>
<td>129 (25%)</td>
<td>38 (28%)</td>
<td>38 (30%)</td>
<td>28 (23%)</td>
<td>25 (19%)</td>
<td>0.10</td>
</tr>
</tbody>
</table>

Abbreviations: Q1 to Q4, quartile 1 to quartile 4.

The multivariable ordinal logistic regression analysis model included age; sex; year of diagnosis; family history of colorectal cancer in parent or sibling; tumor location; tumor differentiation; MSI; CpG island methylator phenotype; KRAS, BRAF, and PIK3CA mutations; and LINE-1 methylation level. A backward stepwise elimination with a threshold of P = 0.05 was used to select variables in the final models. Variables remaining in the final multivariable ordinal logistic regression models are shown in Supplementary Table S2.

Table 4. The association of tumor MIR21 expression with the density of T cells

<table>
<thead>
<tr>
<th>Model for CD3⁺ cell density (n = 518, as an outcome variable)</th>
<th>Univariable OR (95% CI)</th>
<th>Multivariable OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIR21 expression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q1 (lowest)</td>
<td>1 (reference)</td>
<td>1 (reference)</td>
</tr>
<tr>
<td>Q2 (second)</td>
<td>0.88 (0.57-1.36)</td>
<td>0.85 (0.55-1.31)</td>
</tr>
<tr>
<td>Q3 (third)</td>
<td>0.67 (0.43-1.04)</td>
<td>0.59 (0.37-0.92)</td>
</tr>
<tr>
<td>Q4 (highest)</td>
<td>0.47 (0.31-0.73)</td>
<td>0.44 (0.28-0.68)</td>
</tr>
<tr>
<td>P&lt;sub&gt;trend&lt;/sub&gt; &lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.0004</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Model for CD8⁺ cell density (n = 510, as an outcome variable)

<table>
<thead>
<tr>
<th>MIR21 expression</th>
<th>Univariable OR (95% CI)</th>
<th>Multivariable OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 (lowest)</td>
<td>1 (reference)</td>
<td>1 (reference)</td>
</tr>
<tr>
<td>Q2 (second)</td>
<td>1.14 (0.74-1.77)</td>
<td>1.25 (0.80-1.96)</td>
</tr>
<tr>
<td>Q3 (third)</td>
<td>0.72 (0.46-1.12)</td>
<td>0.76 (0.48-1.19)</td>
</tr>
<tr>
<td>Q4 (highest)</td>
<td>0.89 (0.58-1.38)</td>
<td>0.99 (0.63-1.54)</td>
</tr>
<tr>
<td>P&lt;sub&gt;trend&lt;/sub&gt; &lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.27</td>
<td>0.50</td>
</tr>
</tbody>
</table>

Model for CD45RO⁻ cell density (n = 522, as an outcome variable)

<table>
<thead>
<tr>
<th>MIR21 expression</th>
<th>Univariable OR (95% CI)</th>
<th>Multivariable OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 (lowest)</td>
<td>1 (reference)</td>
<td>1 (reference)</td>
</tr>
<tr>
<td>Q2 (second)</td>
<td>0.70 (0.46-1.09)</td>
<td>0.72 (0.46-1.12)</td>
</tr>
<tr>
<td>Q3 (third)</td>
<td>0.57 (0.37-0.89)</td>
<td>0.54 (0.34-0.84)</td>
</tr>
<tr>
<td>Q4 (highest)</td>
<td>0.45 (0.29-0.70)</td>
<td>0.41 (0.26-0.64)</td>
</tr>
<tr>
<td>P&lt;sub&gt;trend&lt;/sub&gt; &lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.0002</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Model for FOXP3⁺ cell density (n = 495, as an outcome variable)

<table>
<thead>
<tr>
<th>MIR21 expression</th>
<th>Univariable OR (95% CI)</th>
<th>Multivariable OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1 (lowest)</td>
<td>1 (reference)</td>
<td>1 (reference)</td>
</tr>
<tr>
<td>Q2 (second)</td>
<td>0.98 (0.63-1.54)</td>
<td>0.93 (0.59-1.46)</td>
</tr>
<tr>
<td>Q3 (third)</td>
<td>0.73 (0.47-1.14)</td>
<td>0.61 (0.39-0.96)</td>
</tr>
<tr>
<td>Q4 (highest)</td>
<td>0.66 (0.42-1.02)</td>
<td>0.55 (0.35-0.86)</td>
</tr>
<tr>
<td>P&lt;sub&gt;trend&lt;/sub&gt; &lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.032</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Abbreviations: Q1 to Q4, quartile 1 to quartile 4.

*The multivariable ordinal logistic regression analysis model included age; sex; year of diagnosis; family history of colorectal cancer in parent or sibling; tumor location; tumor differentiation; MSI; CpG island methylator phenotype; KRAS, BRAF, and PIK3CA mutations; and LINE-1 methylation level. A backward stepwise elimination with a threshold of P = 0.05 was used to select variables in the final models. Variables remaining in the final multivariable ordinal logistic regression models are shown in Supplementary Table S2.

*P<sub>trend</sub> value was calculated by the linear trend across the ordinal (first to fourth quartile) categories of tumor MIR21 expression as a continuous variable in the ordinal logistic regression model for the density of CD3⁺, CD8⁺, CD45RO⁻, or FOXP3⁺ T cells.
population-based data support an immunosuppressive role of MIR21 in colorectal cancer.

High densities of CD3\(^+\) pan-T cells and T-cell subpopulations (CD8\(^+\), CD45RO\(^+\), and FOXP3\(^+\) T cells) in colorectal carcinoma have been associated with better patient survival, indicating a major role of T-cell–mediated adaptive immunity in inhibiting colorectal tumor progression (39–41). Therefore, both tumor molecular and immunity analyses are increasingly important in cancer research and clinical practice. miRNAs play substantial roles in carcinogenesis and immunity and are potential biomarkers or therapeutic targets (42). One possible mechanism of the immunosuppressive effect of MIR21 is based on its ability to suppress the expression of PDCD4, which normally inhibits the translation of IL10 mRNA. Without this suppression, more IL10 is present in the tumor microenvironment (22, 23), which inhibits the antigen-presenting capacities of dendritic cells (25). Tumor MIR21 expression has been shown to inversely correlate with tumor PDCD4 expression assessed by immunohistochemistry on human colorectal cancer tissue (43, 44). Taken together from these findings, it seems to be plausible that MIR21 may suppress antitumor immune responses through increased IL10 in colorectal cancer. In addition, emerging evidence indicates that MIR21 suppresses tumor expression of HPGD [hydroxyprostaglandin dehydrogenase 15-(NAD); or 15-PDGH], which converts PGE2 to its biologically inactive metabolite (24). Hence, MIR21 may increase PGE2 in the tumor microenvironment, which can lead to suppression of antitumor T-cell–mediated adaptive immunity (26). Our human population-based data, along with these lines of experimental evidence, support the hypothesis that MIR21 suppresses antitumor immune responses in colorectal cancer, although additional studies are needed to clarify the exact mechanism. miRNA-targeting therapies for human disease, including cancer, are currently being investigated (42, 45, 46). In light of our findings, it would be intriguing for future research to explore a potential strategy of inhibiting MIR21 and thus its immunosuppressive effect in immunotherapy and prevention for colorectal cancer.

Higher tumor MIR21 expression was associated with BRAF mutation in the present study, which has not been examined in colorectal cancer before. Oncogenic mutation of BRAF activates the MAPK signaling pathway (47). Experimental evidence suggests that activation of the RAF–MAPK signaling pathway may increase MIR21 expression in cancer (48). Taken together from these findings, BRAF mutation might increase MIR21 expression through activation of the MAPK signaling pathway, although additional experimental studies are needed to test this hypothesis.

One limitation of this study is its cross-sectional nature. Hence, we cannot exclude a possibility of reverse causation. It is possible that the interaction of T cells with tumor cells might cause low expression of MIR21 in tumors. However, our specific hypothesis was based on several lines of experimental evidence, indicating that MIR21 suppresses T-cell–mediated immune response to tumor (22–26). Because experimental systems cannot perfectly recapitulate the complexities of human tumors or the immune system, analyses of human population are essential in translational medicine. Another limitation is measurement of MIR21 expression in colorectal cancer tissue, which contains a mixture of neoplastic and nonneoplastic cells, including immune cells. Nonetheless, a number of studies have shown that MIR21 is expressed in neoplastic cells, but not substantially in immune cells (20, 21). We also recognize the limitations in evaluating T cells in human colorectal cancer tissue. We evaluated the well-characterized T-cell markers, such as CD3, CD8, CD45RO, and FOXP3, with the use of TMA immunohistochemistry and computer-assisted image analysis to objectively quantify the T-cell densities in a large number of cases. The favorable prognostic associations of the densities of these T-cell populations in our cohort studies were consistent with the results of previous studies in other populations (6, 8), suggesting that the density of T cells, as assessed by immunohistochemistry, might be considered a reliable measure of the adaptive immune response to colorectal tumors.

Strengths of this study include the use of our molecular pathological epidemiology database of more than 500 colorectal cancer cases in the two U.S. nationwide, prospective cohort studies, which integrates epidemiologic exposures, clinicopathologic features, key tumor molecular features, and immune reaction status in colorectal cancer tissue (49, 50). This population-based colorectal cancer database enabled us to rigorously examine the association of tumor MIR21 expression with the density of T cells, controlling for potential confounders. In addition, our colorectal cancer specimens were derived from a large number of hospitals in diverse settings across the United States (but not based on a limited number of hospitals), which increases the generalizability of our findings. As another strength, we used robust laboratory assays, including miRNA analysis and tissue image analysis that could objectively quantify specific T cells in tumor tissue.

In conclusion, tumor MIR21 expression is inversely associated with the densities of CD3\(^+\) and CD45RO\(^+\) T cells in colorectal cancer tissue. Our data support a possible role of MIR21 in downregulating antitumor T-cell–mediated adaptive immunity, and suggest MIR21 as a potential target for immunotherapy and immunoprevention in colorectal cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

The former Editor-in-Chief of this journal (Glenn Dranoff) is an author on this article. In keeping with the AACR’s editorial policy, the peer review of this submission was managed by a senior member of Cancer Immunology Research’s editorial team; a member of the AACR Publications Committee rendered the final decision concerning acceptability.

Disclaimer
The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.

Authors’ Contributions
Conception and design: K. Miina, M. Loda, C.S. Fuchs, Z.R. Qian, S. Ogino
Development of methodology: K. Miina, M. Bowden, M. Loda, C.S. Fuchs, Z.R. Qian, S. Ogino
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Miina, K. Inamura, Y. Sukawa, A. Masuda, J. Yang, R. Dou, K. Nosho, M. Bowden, M. Loda, A.T. Chan, C.S. Fuchs, S. Ogino
Writing, review, and/or revision of the manuscript: K. Miina, R. Nishihara, J.A. Nowak, S.A. Kim, M. Song, J. Yang, H. Baba, E.L. Giovannucci, G. Dranoff, G.J. Freeman, A.T. Chan, C.S. Fuchs, Z.R. Qian, S. Ogino
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.A. Kim, A. Masuda, J. Yang, R. Dou, A.T. Chan, S. Ogino

Study supervision: A.T. Chan, C.S. Fuchs, Z.R. Qian, S. Ogino

Acknowledgments

The authors thank the participants and staff of the Nurses’ Health Study and the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, MA, MD, ME, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WV. The authors assume full responsibility for analyses and interpretation of the data.

Use of Standardized Official Symbols

We use HUGO (Human Genome Organisation)-approved official symbols for genes and gene products, including BRAF, CACNA1G, CD3, CD8, CD274, CD4, CD56, CD19, CD16, CD34, CCR7, CCR2, CCR5, CXCL9, CXCL10, RAG1, RAG2, SEK1, SEK2, STAT1, STAT3, TXNIP, and TYK2; all of which are described at www.genenames.org. Gene names are italicized, and gene product names are not italicized.

References

MicroRNA MIR21 and T Cells in Colorectal Cancer

Kosuke Mima, Reiko Nishihara, Jonathan A. Nowak, et al.

Cancer Immunol Res  Published OnlineFirst September 29, 2015.

Updated version Access the most recent version of this article at: doi:10.1158/2326-6066.CIR-15-0084

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.